Extracurricular laboratory:new discovery of 214045-84-8

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.214045-84-8, you can also check out more blogs about214045-84-8

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 214045-84-8, name is 6-Fluoro-3,4-dihydroisoquinolin-1(2H)-one, introducing its new discovery. 214045-84-8

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.214045-84-8, you can also check out more blogs about214045-84-8

Reference£º
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem